Revelation Biosciences Stock Performance
| REVB Stock | USD 2.98 0.14 4.93% |
The company holds a Beta of 0.52, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Revelation Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Revelation Biosciences is expected to be smaller as well. At this point, Revelation Biosciences has a negative expected return of -0.7%. Please make sure to check Revelation Biosciences' potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Revelation Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Revelation Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 4.93 | Five Day Return 2.76 | Year To Date Return (71.65) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:16 | Last Split Date 2025-01-28 |
1 | Nasdaq Grants Revelation Biosciences Inc. Continued Listing | 01/06/2025 |
2 | Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 | 01/13/2025 |
3 | Revelation Biosciences stock hits 52-week low at 0.28 - Investing.com | 01/24/2025 |
4 | Acquisition by Tidmarsh George F of 181 shares of Revelation Biosciences at 3.87 subject to Rule 16b-3 | 02/11/2025 |
5 | Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval | 02/24/2025 |
6 | Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 | 03/06/2025 |
7 | Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference | 03/13/2025 |
8 | Revelation Biosciences, Inc. Short Interest Down 31.1 percent in February | 03/17/2025 |
| Begin Period Cash Flow | 12 B |
Revelation |
Revelation Biosciences Relative Risk vs. Return Landscape
If you would invest 563.00 in Revelation Biosciences on December 25, 2024 and sell it today you would lose (265.00) from holding Revelation Biosciences or give up 47.07% of portfolio value over 90 days. Revelation Biosciences is currently does not generate positive expected returns and assumes 9.0122% risk (volatility on return distribution) over the 90 days horizon. In different words, 80% of stocks are less volatile than Revelation, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Revelation Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revelation Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Revelation Biosciences, and traders can use it to determine the average amount a Revelation Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0774
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | REVB |
Estimated Market Risk
| 9.01 actual daily | 80 80% of assets are less volatile |
Expected Return
| -0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Revelation Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revelation Biosciences by adding Revelation Biosciences to a well-diversified portfolio.
Revelation Biosciences Fundamentals Growth
Revelation Stock prices reflect investors' perceptions of the future prospects and financial health of Revelation Biosciences, and Revelation Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revelation Stock performance.
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | (3.8 M) | ||||
| Shares Outstanding | 905.23 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (7.98 B) | ||||
| Net Income | (15.04 B) | ||||
| Cash And Equivalents | 3.48 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 1.91 B | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 0.68 X | ||||
| Book Value Per Share | 9.02 X | ||||
| Cash Flow From Operations | (18.32 B) | ||||
| Earnings Per Share | (87.68) X | ||||
| Market Capitalization | 2.7 M | ||||
| Total Asset | 6.62 B | ||||
| Retained Earnings | (40.51 B) | ||||
| Working Capital | 4.65 M | ||||
About Revelation Biosciences Performance
By analyzing Revelation Biosciences' fundamental ratios, stakeholders can gain valuable insights into Revelation Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Revelation Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revelation Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.27) | (2.38) | |
| Return On Capital Employed | (1.20) | (1.14) | |
| Return On Assets | (2.27) | (2.38) | |
| Return On Equity | (3.19) | (3.03) |
Things to note about Revelation Biosciences performance evaluation
Checking the ongoing alerts about Revelation Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Revelation Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Revelation Biosciences generated a negative expected return over the last 90 days | |
| Revelation Biosciences has high historical volatility and very poor performance | |
| Revelation Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Revelation Biosciences currently holds 1.91 B in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revelation Biosciences has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Revelation Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.04 B) with profit before overhead, payroll, taxes, and interest of 90.91 M. | |
| Revelation Biosciences currently holds about 3.48 M in cash with (18.32 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. | |
| Latest headline from thelincolnianonline.com: Revelation Biosciences, Inc. Short Interest Down 31.1 percent in February |
- Analyzing Revelation Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revelation Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Revelation Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revelation Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revelation Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Revelation Biosciences' stock. These opinions can provide insight into Revelation Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Revelation Stock analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| CEOs Directory Screen CEOs from public companies around the world |